Approved Study Database

Ref. No. Scientific Title Principal investigator
2025.828 Sinonasal symptoms and quality of life changes after total laryngectomy among Hong Kong patients: A cross-sectional analysis Dr. Yeung David
David Chun Man Yeung
2024.099 A Randomised Controlled Trial of Ultrasound Guided Radiofrequency Ablation of Parotid Warthin's Tumor versus Parotidectomy Dr. YEUNG David
David Chun Man
2026.088 Efficacy of nurse-led video-guided olfactory training and telephone follow-up on improving olfactory training therapy adherence: a randomized controlled trial. Dr. Yeung David
2026.206 A Visual Mapping Approach to CT Scoring in Chronic Rhinosinusitis: A Prospective Crossover Study of Efficacy and Reliability Dr. Yeung David
2008.147 Validity and Reliability of Skinfold Thickness Measurement in Assessing Body Density and Body Fatness in Chinese Children in Hong Kong Aged 6-19 Years Using Air Displacement Plethysmography as a Criterion Measure Mr Yeung Daniel Chi Shing
2016.183 Impact of a Home-based Pharmaceutical Care Service on Medication Adherence and Quality of Life : A prospective observational study Ms. YEUNG Ching Ying
楊靜瀅
2017.620 The effect of posture brace on balance in patients with osteoporotic vertebral fracture Miss YEUNG Ching Wing
楊靜穎
2019.438 Effects of An Advance Care Planning Programme for Persons With Early Dementia or Mild Cognitive Impairment And Their Family Caregivers in the Community: A Randomized Controlled Trial Ms. YEUNG Chi Yan
楊智恩
2009.279 How does spinal stenosis affects the health-related quality of life of Chinese older people? Miss Yeung Chi Yan
2005.160 The Effect of Therapeutics Ultrasound in Healing Reptured Achilles Tendon in Human YEUNG Chi Keung
2017.514 Gut microbiome of individuals with metabolic syndrome Dr. YEOH Yun Kit
2018.008 Genome-based resolution of gut microbiomes and viromes in patients with metabolic syndrome Dr. YEOH Yun Kit
2020.015 Effects of commercial antimicrobial mouthwash on oral microbial community composition Dr. YEOH Yun Kit
2020.354 Tender for the Provision of Services of the Monitoring and Evaluation Study of Kwai Tsing District Health Centre and Sham Shui Po District Health Centre Prof. YEOH Eng Kiong
楊永強
2021.696 Health Support Pilot Programme for South Asian Ethnic Groups Prof. YEOH Eng Kiong
楊永強
2014.551 Improving elderly healthcare voucher scheme to incentivise primary care in Hong Kong: How has health service utilization changed Prof. YEOH Eng Kiong
2017.193 Modelling the Impact of Control Strategies for Tuberculosis Transmission in Hong Kong Prof. YEOH Eng Kiong
2015.359 Quality of healthcare for the Ageing – Health system and service models to better cater for an ageing population Prof. YEOH Eng Kiong
2026.566 Health Services Utilization and Health Outcomes of HA patients: Population Trend, Individual Trajectories, and Impact of Policy Prof. Yeoh Eng Kiong
2023.102 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 Prof. YEO Winnie Ming Ming
2021.219 A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Prof. YEO Winnie
楊明明教授
2022.173 EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation Prof. YEO Winnie
楊明明教授
2022.510 A Multinational, Multicenter, Non-Interventional, Retrospective, Observational, Real-World Study: Treatment Patterns in Patients with HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in East Asia (HER2+ GASTA Study) Prof. YEO Winnie
楊明明
2022.282 A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study Prof. YEO Winnie
楊明明教授
2022.286 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 Prof. YEO Winnie
楊明明教授
2021.162 A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy Prof. YEO Winnie
楊明明教授
2022.285 A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-102) Prof. YEO Winnie
楊明明
2023.267 A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy Prof. YEO Winnie
2021.563 A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer Prof. YEO Winnie
楊明明教授
2023.269 A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2- early breast cancer (Adjuvant WIDER) Prof. YEO Winnie
2020.653 A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) Prof. YEO Winnie
楊明明教授
2018.392 A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE-859) Prof. YEO Winnie
楊明明
2019.476 A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER Prof. YEO Winnie
楊明明 教授
2020.330 Scalp Cooling Study for the Prevention of Chemotherapy-induced Alopecia in Chinese Breast Cancer Patients Prof. YEO Winnie
楊明明教授
2018.363 A RETROSPECTIVE STUDY ON EFFICACY AND TOLERABILITY OF COMBINATION FLOT CHEMOTHERAPY AS NEOADJUVANT CHEMOTHERAPY IN GASTRIC CANCER PATIENTS Prof. YEO Winnie
楊明明
2019.551 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER Prof. YEO Winnie
楊明明 教授
2018.528 A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PATIENT PREFERENCE AND SATISFACTION OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER Prof. YEO Winnie
楊明明 教授
2020.258 A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. Prof. YEO Winnie
楊明明
2018.435 A Phase 3, multicenter, randomized, open-label, active-controlled study of Trastuzumab Deruxtecan (DS-8201A), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane (DESTINY-Breast03) Prof. YEO Winnie
楊明明
2013.417 GASTRIC CANCER PATIENTS RECEIVING ADJUVANT TS-1- A SURVEY ON PATIENTS’ TOLERABILITY Prof. YEO Winnie
1995.526 Randomized Trial of High-Dose Epirubicin and Cyclophamide x 3 Supported by Peripheral Blood Projector Cells Versus Anthracycline and Cyclophosphamide x 4 Followed by Cyclophosphamide, Methotrexate & 5- Fluorouracil as Adjuvant Treatment for High Risk Operable Stage II and Stage III Breast Cancer in Premenopausal and Young Postmenopausal (<65 yrs) Patients Prof. YEO Winnie
2009.158 Effect of Genetic Polymorphisms and Gene Expression in Chemotherapy-Related Toxicities in Chinese Breast Cancer Patients Prof. Yeo Winnie
2008.090 Identification of Tumor Suppressor Function and Prognostic Role of Deleted in Lung and Esophageal Cancer 1 (DLEC1) Gene in Hepatocellular Carcinoma Prof. YEO Winnie
2009.077 Clinical Application of Genetic Markers in Prediction of Doxorubicin and Taxane Induced Cytotoxicity in Mammary Cancer Patients of Asian Ethnicity Prof. Yeo Winnie
2010.326 A longitudinal study of psychosocial needs and psychological distress of Chinese women with advanced breast cancer: A follow-up study Prof. YEO Winnie
2011.196 Quality of life of Chinese patients with hepatocellular carcinoma and its value as prognosticator for the disease Prof. Yeo Winnie
2010.204 Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B treated with anti-B cell therapy-Effective and Cost-Effectiveness of prevention Prof. Yeo Winnie
2010.092 Predictors of Hepatitis B Virus Reactivation after Lamivudine Prophylaxis for Chemotherapy Prof. Yeo Winnie
2012.158 Design Innovation and Customisation of the Mastectomy Bra and Prosthesis for Hong Kong Mastectomy Patients: A Multidisciplinary Approach Prof. YEO Winnie
2008.294 A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab Prof Yeo Winnie

Page 15 of 289.